Nemes Rush Group
DGX icon

Nemes Rush Group’s Quest Diagnostics DGX Stock Holding History

Nemes Rush Group’s Portfolio DGX Stock Details DGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$1.63K Hold
7
– – ﹤0.01% 789
2026
Q2 		$1.48K Hold
7
– – ﹤0.01% 825
2026
Q1 		$1.37K Hold
7
– – ﹤0.01% 789
2025
Q4 		$1.22K Hold
7
– – ﹤0.01% 790
2025
Q3 		$1.33K Hold
7
– – ﹤0.01% 618
2025
Q2 		$1.26K Hold
7
– – ﹤0.01% 635
2025
Q1 		$1.18K Hold
7
– – ﹤0.01% 641
2024
Q4 		$1.06K Buy
+7
New +$1.09K ﹤0.01% 660

Other funds holding DGX

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
M&G plc
M&G plc London, United Kingdom $19.9B AUM 15.09% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return
DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $87.8B AUM 20.94% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $195B AUM 21.17% 1-Year Est. Return
Amundi
Amundi Paris, France $496B AUM 35.36% 1-Year Est. Return
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $91.6B AUM 30% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return

Nemes Rush Group's DGX Position: Q3 2026 in Review

Nemes Rush Group held its Quest Diagnostics (DGX) position steady in Q3 2026 at 7 shares worth $1.63K. The position accounts for ﹤0.01% of the portfolio, ranked #789.

Nemes Rush Group first reported a position in DGX in Q4 2024 and has held it in 8 quarters since. 605 funds tracked by Wall St. Rank hold DGX as of Q3 2026.

  • Nemes Rush Group held 7 shares of Quest Diagnostics worth $1.63K as of Q3 2026.
  • Nemes Rush Group left its Quest Diagnostics share count unchanged in Q3 2026.
  • Quest Diagnostics made up ﹤0.01% of Nemes Rush Group's portfolio in Q3 2026, its #789 holding.
  • Nemes Rush Group first reported a position in Quest Diagnostics in Q4 2024 and has held it in 8 quarters since.
  • 605 funds tracked by Wall St. Rank held Quest Diagnostics as of Q3 2026.

Based on Nemes Rush Group's 13F filing for Q3 2026, filed 4 Nov 2026.